Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

An area correction method to reduce intrasubject variability in bioequivalence studies.

H Y Abdallah1

  • 1Division of Biopharmaceutics, Center for Drug Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, USA. hisham.abdallah@roche.com

Journal of Pharmacy & Pharmaceutical Sciences : a Publication of the Canadian Society for Pharmaceutical Sciences, Societe Canadienne Des Sciences Pharmaceutiques
|August 17, 2000
PubMed
Summary

Area correction using AUC*K improves bioequivalence study outcomes when high intrasubject variability in clearance is present. This method is particularly beneficial for drugs with low intrinsic clearance, aiding regulatory decisions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Long Noncoding RNAs MEG3, TUG1, and hsa-miR-21-3p Are Potential Diagnostic Biomarkers for Coronary Artery Disease].

Molekuliarnaia biologiia·2023
Same author

Methemoglobinemia induced by topical benzocaine: a warning for the endoscopist.

Endoscopy·2002
Same author

A spreadsheet program for simulation of bioequivalence and bioavailability studies.

Computers in biology and medicine·1995
Same author

Stability and sorption of FK 506 in 5% dextrose injection and 0.9% sodium chloride injection in glass, polyvinyl chloride, and polyolefin containers.

American journal of hospital pharmacy·1992
Same author

In-vitro interaction of a novel immunosuppressant, FK 506, and antacids.

The Journal of pharmacy and pharmacology·1991
Same author

Pharmacokinetics of ceftriaxone in liver-transplant recipients.

Journal of clinical pharmacology·1991

Area of Science:

  • Pharmacokinetics and Drug Development
  • Bioequivalence Study Design
  • Statistical Analysis in Pharmacology

Background:

  • Intrasubject variability poses challenges in bioequivalence studies.
  • Accurate assessment of drug product equivalence is crucial for regulatory approval.
  • Traditional pharmacokinetic parameters may be influenced by variability in clearance.

Purpose of the Study:

  • To investigate the utility of a corrected area (AUC*K) to mitigate intrasubject variability in bioequivalence assessments.
  • To evaluate the impact of area correction on bioequivalence outcomes for drugs with differing pharmacokinetic profiles.

Main Methods:

  • Computer simulations of two-way crossover bioequivalence trials for two drugs with distinct intrinsic clearance (Cl(int)) values.

Related Experiment Videos

  • Application of area correction (AUC*K) alongside standard analysis (AUC, Cmax) using ANOVA.
  • Simulation of high intrasubject coefficient of variation (CV) for clearance (30%) and other parameters (10%).

    • Main Results:

    • Area correction (AUC*K) significantly increased the number of trials passing bioequivalence criteria for drugs with high intrasubject variability in clearance.
    • The benefit of AUC*K was more pronounced for drugs with low intrinsic clearance compared to those with high intrinsic clearance.
    • Variability in other parameters like volume of distribution (V) did not consistently improve with area correction.

    Conclusions:

    • Area correction (AUC*K) is a potentially valuable tool for bioequivalence studies characterized by high intrasubject variability in clearance.
    • The method shows promise for drugs with low intrinsic clearance, where clearance variability impacts systemic exposure.
    • Further evaluation is needed to determine the role of AUC*K in regulatory decision-making for bioequivalence.